NCT06055816 Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
| NCT ID | NCT06055816 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-09-28 |
| Primary Completion | 2024-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2023-09-28 with a primary completion date of 2024-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Eligibility Criteria
Inclusion Criteria: * Aged ≥65 years with newly pathologically confirmed NPC * Karnofsky performance status ≥60 * Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition) * Adequate organ function Exclusion Criteria: * Cancer history * Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy * Life-expectance within 6 months
Contact & Investigator
Xiaozhong Chen
PRINCIPAL INVESTIGATOR
Department of Radiation Oncology, Zhejiang Cancer Hospital
Frequently Asked Questions
Who can join the NCT06055816 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06055816 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06055816 currently recruiting?
Yes, NCT06055816 is actively recruiting participants. Contact the research team at chenxz@zjcc.org.cn for enrollment information.
Where is the NCT06055816 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06055816 clinical trial?
NCT06055816 is sponsored by Zhejiang Cancer Hospital. The principal investigator is Xiaozhong Chen at Department of Radiation Oncology, Zhejiang Cancer Hospital. The trial plans to enroll 40 participants.